Ferric citrate hydrate improves transferrin saturation in patients with low levels of transferrin saturation undergoing hemodialysis

• Published in: Renal failure 2024-12, Vol.46 (2), p.2395449
• Main Authors: Yokoyama, Keitaro, Inoue, Ryo, Ito, Kyoko, Mitobe, Yuko
• Format: Article
• Language: English
• Subjects: Aged; Anemia and Hematologic Disorders; Anemia, Iron-Deficiency - blood; Anemia, Iron-Deficiency - drug therapy; chronic kidney disease; dialysis; Female; ferric citrate hydrate; Ferric Compounds - administration & dosage; Ferric Compounds - therapeutic use; Humans; iron deficiency; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic - blood; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - therapy; Research Letter; Transferrin - analysis; Transferrin - metabolism; transferrin saturation
• ISSN: 0886-022X; 1525-6049; 1525-6049
• DOI: 10.1080/0886022X.2024.2395449

Although it has been established that patients with chronic kidney disease and iron deficiency, as indicated by a transferrin saturation of < 20%, are at increased risk of all-cause mortality and cardiovascular events, the optimal management of such patients has not yet been determined. In this post hoc subgroup analysis, we aimed to clarify the effect of ferric citrate hydrate on transferrin saturation in patients with chronic kidney disease and low transferrin saturation (< 20%) undergoing hemodialysis. To accomplish this, we extracted the relevant data on a subset of patients drawn from two previous studies: the ASTRIO study (A Study examining the contribution to Renal anemia treatment with ferric citrate hydrate, Iron-based Oral phosphate binder, UMIN000019176) and a post-marketing surveillance study. The subset of patients used for the present study were those with baseline transferrin saturation < 20%. We found that administration of ferric citrate hydrate increased transferrin saturation and maintained transferrin saturation at approximately 30%. However, because we did not have access to data on all-cause mortality or cardiovascular events, we could not ascertain whether the frequency of these outcomes was reduced in parallel with improvements in transferrin saturation. Further large studies are required.